Igor Grachev, MD, PhD
Global Clinical Development Leader
TEVA Branded Pharmaceuticals
At present Igor Grachev, MD, PhD is a New Growth Franchise Global Head, Clinical, Medical and Drug Safety, Novartis Consumer Health, Inc, Parsippany, New Jersey. Earlier he was a Neurologist, Psychiatrist, Neuroscientist, Drug Developer, Translational Medicine/POC, Clinical Development, Medical Affairs and Imaging expert with over 20 years of extensive Pharma industry, academic and CRO biomedical research experience who has had roles of increasing responsibility and scope at MGH/Harvard Medical School, SUNY Upstate Medical University, Schering-Plough, Sanofi-Aventis, Merck, BioClinica, Merck Sharp & Dohme Corp, GE Healthcare, and Novartis Consumer Health. All his industry roles have involved the application of imaging, biomarkers and clinical neuroscience to drug development.
His research interests include: Neurobiology of Neurodegenerative disorders (Parkinson’s disease, Alzheimer’s disease, Multiple Sclerosis), Insomnia (incl. PSG), OCD, Depression, Anxiety, Schizophrenia, ADHD, Migraine, Acute & Chronic Pain, Stroke and other indications. Expert in clinical biomarkers and the following Imaging modalities: PET, SPECT, and MRI (Gd-MRI, vMRI, fMRI, MRS, DCE-MRI).
Dr. Grachev is a member of the Coalition Against Major Diseases (CAMD), QIBA DCE-MRI, FDG- and amyloid-PET steering committees of RSNA, ADNI and ADNI2, Society of Nuclear Medicine, International Society to Advance Alzheimer Research and Treatment. He served as a Chair of Industry Scientific Advisory Board for Parkinson’s Progression Markers Initiative, Michael J. Fox Foundation, 2010-2011.
He has written and co-authored over 100 clinical research scientific publications including chapters on imaging biomarkers/technologies in three books.
1. Grachev I. Methods in Pain Research. CRC Press.
2. Grachev I. Complex Regional Pain Syndrome. IASP Press
3. Grachev I. Imaging in CNS Drug Development. Springer Science NY.